Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).

Nobuaki SuzukiShoichi HazamaTakeshi NagasakaHiroaki TaniokaYasuo IwamotoYuji NegoroMasami YamauchiMichiya KobayashiHiroshi OkudaNoriaki FujishimaTaku NishimuraNaoki YamanakaKazuhiro ToyotaYoshiko MoriYuki NakagamiMototsugu ShimokawaHiroaki NaganoMasazumi Okajima

Published in: International journal of clinical oncology (2019)

In mCRC patients, biweekly CAPIRI + bevacizumab appears effective and feasible as a second-line chemotherapy with relatively low toxicities, and has potential as a useful substitute for FOLFIRI + bevacizumab.

Keyphrases

study protocol
metastatic colorectal cancer
phase ii study
clinical trial
end stage renal disease
locally advanced
double blind
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
squamous cell carcinoma
cross sectional
cell therapy
climate change
patient reported